WASHINGTON – Arena Pharmaceuticals Inc.'s shares (Nasdaq:ARNA) nose dived 39.7 percent Tuesday after FDA reviewers said they could not definitively conclude that the firm's experimental weight loss drug lorcaserin was devoid of valvulopathy-related cardiac effects.